Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glasdegib - Pfizer

Drug Profile

Glasdegib - Pfizer

Alternative Names: DAURISMO; PF 04; PF-04449913; PF-4449913

Latest Information Update: 03 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular; H. Lee Moffitt Cancer Center and Research Institute; Pfizer
  • Class Antineoplastics; Benzimidazoles; Phenylurea compounds; Piperidines; Small molecules
  • Mechanism of Action Hedgehog cell-signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Acute myeloid leukaemia
  • Phase II Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Phase I/II Glioblastoma; Graft-versus-host disease
  • Phase I Cancer; Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Dec 2018 Pharmacodynamics and safety data from the phase Ib/II BRIGHT 1003 trial in Acute myeloid leukaemia presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-HEM-2018)
  • 26 Nov 2018 Glasdegib is still in Phase I clinical trials for Solid tumours in USA (PO) (Pfizer pipeline, November 2018)
  • 26 Nov 2018 Glasdegib is still in Phase I clinical trials for Haematological malignancies in Italy (PO) (Pfizer pipeline, November 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top